Basilea Pharmaceutica AG (0QNA.L)

CHF 41.65

(-2.93%)

Market Cap (In CHF)

504.84 Million

Revenue (In CHF)

157.63 Million

Net Income (In CHF)

10.45 Million

Avg. Volume

4885.00

Currency
CHF
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
32.2-51.3
PE
-
EPS
-
Beta Value
0.739
ISIN
CH0011432447
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Mr. David Veitch
Employee Count
-
Website
https://www.basilea.com
Ipo Date
2014-03-07
Details
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

More Stocks